News and Trends 1 Jun 2023
SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy
CRISPR-based microbial gene therapy company SNIPR Biome ApS has announced positive interim clinical results from its phase 1 clinical trial with SNIPR001. SNIPR Biome’s SNIPR001 is the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. The work was supported by CARB-X, a global […]